ProjectBI 1199.247
Basic data
Title:
BI 1199.247
Duration:
09/06/2017 to 30/09/2023
Abstract / short description:
A double blind, randomized, placebo-controlled trial evaluating
the efficacy and safety of nintedanib over 52 weeks in patients
with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
the efficacy and safety of nintedanib over 52 weeks in patients
with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Involved staff
Managers
Faculty of Medicine
University of Tübingen
University of Tübingen
Local organizational units
Internal Medicine Department II
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Ingelheim am Rhein, Rheinland-Pfalz, Germany